Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98778 | 0.81 | PPARD (0.38) | — | |
| SCHEMBL1319863 | 0.79 | — | — | |
| SCHEMBL6437928 | 0.78 | — | — | |
| SCHEMBL28389789 | 0.78 | PTPN1 (0.31) | — | |
| SCHEMBL10930331 | 0.78 | CYP4F2 (0.37) | LMNA | |
| SCHEMBL29690413 | 0.77 | FDPS (0.31) | — | |
| SCHEMBL282438 | 0.77 | FDPS (0.37) | GRM2GRM3LMNA | |
| SCHEMBL4119345 | 0.75 | LPAR3 (0.48) | — | |
| Hydrochloric Acid SCHEMBL4158783 | 0.75 | FDPS (0.36) | GRM2GRM3LMNA | |
| SCHEMBL2298232 | 0.75 | FDPS (0.36) | GRM2GRM3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554330-B1 | PARTIALLY ESTER-EXCHANGED SIPM AND PROCESS THEREWITH | INVISTA TECH SARL (CH) | 2009-03-11 | — | — | EP | claimed |
| EP-1615934-B1 | TITANIUM CHELATE DISPERSIONS | DU PONT (US) | 2007-06-27 | — | — | EP | claimed |
| CN-106661084-B | Macrocyclic broad spectrum antibiotics | 阿奇克斯制药公司 | 2021-08-31 | — | — | CN | disclosed |
| US-20190047939-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF 17(20)-ENE B-SECO STEROIDS | PATHEON AUSTRIA GMBH & CO KG (AU) | 2019-02-14 | — | — | US | disclosed |
| EP-3423465-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF 17(20)-ENE B-SECO STEROIDS | Patheon Austria GmbH & Co KG (AT) | 2019-01-09 | — | — | EP | disclosed |
| EP-2758402-B9 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2758402-B1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2968336-A2 | COMBINATION OF AN EGFR T790M INHIBITOR AND AN EGFR INHIBITOR FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER | Pfizer Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150203502-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2015-07-23 | — | — | US | disclosed |
| US-9040547-B2 | Pyrrolopyrimidine and purine derivatives | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| WO-2014140989-A2 | COMBINATION OF AN EGFR T790M INHIBITOR AND AN EGFR INHIBITOR FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER | PFIZER INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2000012508-A2 | PYRROLBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000008068-A1 | COMPOSITIONS SUITABLE FOR ELECTROCHEMICAL CELLS | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-17 | — | — | WO | disclosed |
| EP-0970529-A1 | METHOD FOR PRODUCING SHAPED BODIES FOR LITHIUM ION BATTERIES | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999057161-A1 | COMPOSITIONS SUITABLE FOR ELECTROCHEMICAL CELLS | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-11 | — | — | WO | disclosed |
| WO-1998044576-A1 | METHOD FOR PRODUCING SHAPED BODIES FOR LITHIUM ION BATTERIES | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-08 | — | — | WO | disclosed |
| US-5693841-A | Cyclohexanone compounds, process for preparing the same, and processes for preparing silacyclohexane-based liquid crystal compounds from the cyclohexanone compounds | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1997-12-02 | — | — | US | disclosed |
| EP-0765880-A1 | Process for preparing sil acyclohexane-based liquid crystal compounds from silacyclohexanone compounds | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1997-04-02 | — | — | EP | disclosed |
| EP-0687678-A1 | Cyclohexanone compounds, process for preparing the same, and processes for preparing silacyclohexane-based liquid crystal compounds from the cyclohexanone compounds | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1995-12-20 | — | — | EP | disclosed |
| EP-0661271-A1 | AZEPINE DERIVATIVE, PRODUCTION THEREOF, AND USE THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047939-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF 17(20)-ENE B-SECO STEROIDS | CYP17A1, CYP46A1, HSD17B7 | GRM2 2738/4885GRM3 1850/4885LMNA 1634/4885 |
| US-20150203502-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | TYMP, DPYD, TYMS | GRM2 3377/4885GRM3 2910/4885LMNA 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.